Eltrombopag out-of-pocket expenses and medical insurance reimbursement policy explanation

Eltrombopag is an oral small-molecule thrombopoietin receptor agonist, mainly used to treat chronic immune thrombocytopenic purpura (ITP), aplastic anemia (SAA), and hepatitis C-related thrombocytopenia. In recent years, with the increasing demand of domestic patients for the treatment of rare blood diseases, eltrombopag has gradually become popular in the Chinese market and has been officially included in the medical insurance catalog. The implementation of the medical insurance reimbursement policy has greatly reduced the financial burden on patients, allowing more patients who need long-term treatment to take medication stably and continue to benefit.

In terms of cost, the selling price of eltrombopag in the domestic market is relatively stable. The original version of the drug is currently produced by Novartis. The price range in domestic pharmacies is approximately between one or two thousand yuan to four or five thousand yuan. The specific price varies slightly depending on the drug specifications and hospital level. Taking the Indian Novartis version of the original drug as an example, the latest market price of 25mg14 capsules is about RMB1,700 yuan, while the price of 50mg14 capsules is within 3,000 yuan. After being included in medical insurance reimbursement, patients can enjoy a reimbursement ratio of 40%-70% depending on the local medical insurance policy. The actual out-of-pocket amount is significantly reduced, and the financial pressure of long-term treatment is effectively alleviated.

In addition, in addition to the original drug, there are currently multiple overseas generic versions of eltrombopag on the market, such as products from pharmaceutical companies in India, Bangladesh, and Laos. These generic drugs are basically the same as the original drugs in terms of drug ingredients, dosage and clinical effects, but the price is more affordable, generally in the range of several hundred yuan. For patients who cannot obtain medication support through medical insurance channels, the accessibility and cost advantages of generic drugs make them an important alternative, especially in the long-term maintenance treatment phase, which can significantly reduce the total treatment expenditure.

Overall, the medical insurance coverage policy of eltrombopag has brought substantial economic and therapeutic benefits to patients with thrombocytopenia. For patients who are eligible for medical insurance, they should issue prescriptions and go through medical insurance reimbursement procedures through regular medical institutions; while for patients who are not covered by medical insurance or who need continuous medication, they can also choose to purchase lower-priced generic drugs through compliant channels under the guidance of a doctor. In the future, as the domestic drug negotiation mechanism continues to be optimized, the price and reimbursement ratio of eltrombopag are expected to be further reduced, allowing more patients to obtain long-term, stable treatment at a more reasonable cost.

Reference materials:https://www.drugs.com/